SCHEMBL5863206

SCHEMBL5863206

COC(=O)c1ccn2nc(C=CN(C)C)n(Cc3ccccc3)c(=O)c12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ADORA3 P0DMS8 2/20 0.39
MAPK8 P45983 5/20 0.39
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
AR P10275 1/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
ALDH1A1 P00352 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
KIF11 P52732 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863203 1.00 KMT2A (0.39) KMT2AKDM4ESMN1; SMN2ADORA3MAPK8
SCHEMBL5863347 0.87 KMT2A (0.42) KMT2AKDM4ESMN1; SMN2ADORA3MAPK8
SCHEMBL5863118 0.82 KIF11 (0.44) KDM4ESMN1; SMN2ADORA3MAPTGAA
SCHEMBL5863114 0.82 KIF11 (0.44) KDM4ESMN1; SMN2ADORA3MAPTGAA
SCHEMBL7102886 0.79 KIF11 (0.42) KDM4ESMN1; SMN2ADORA3MAPTGAA
Dimethylformamide SCHEMBL7102884 0.77 KIF11 (0.40) ADORA3GAAHPGDKIF11
SCHEMBL5863148 0.76 KIF11 (0.44) KMT2AKDM4ESMN1; SMN2ADORA3MAPK8
SCHEMBL5863407 0.72 TSHR (0.52) KMT2AKDM4ESMN1; SMN2ADORA3GAA
SCHEMBL5863656 0.72 KIF11 (0.41) KMT2AKDM4ESMN1; SMN2ADORA3MAPK8
SCHEMBL5863491 0.68 KIF11 (0.42) KDM4ESMN1; SMN2MAPTGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030118-B2 Pyrrolotriazinone compounds and their use to treat diseases BRISTOL-MYERS SQUIBB COMPANY (US) 2006-04-18 US disclosed
US-20030232832-A1 Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents BRISTOL-MYERS SQUIBB COMPANY 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232832-A1 Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents CCNB1, NUMA1, CCNA1 KMT2A 325/4885KDM4E 1096/4885SMN1; SMN2 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.